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We describe a simpliﬁ  ed model, based on the current 
economic and health effects of human papillomavirus (HPV), 
to estimate the cost-effectiveness of HPV vaccination of 
12-year-old girls in the United States. Under base-case pa-
rameter values, the estimated cost per quality-adjusted life 
year gained by vaccination in the context of current cervical 
cancer screening practices in the United States ranged from 
$3,906 to $14,723 (2005 US dollars), depending on factors 
such as whether herd immunity effects were assumed; the 
types of HPV targeted by the vaccine; and whether the ben-
eﬁ  ts of preventing anal, vaginal, vulvar, and oropharyngeal 
cancers were included. The results of our simpliﬁ  ed mod-
el were consistent with published studies based on more 
complex models when key assumptions were similar. This 
consistency is reassuring because models of varying com-
plexity will be essential tools for policy makers in the devel-
opment of optimal HPV vaccination strategies.
I
n 2000, the Institute of Medicine (IOM) published a re-
port listing 26 candidate vaccines that potentially could 
be developed and licensed in the ﬁ  rst 2 decades of the 21st 
century (1). Included in this list was a candidate vaccine for 
human papillomavirus (HPV), a virus that can cause cervi-
cal and other anogenital cancers, genital warts, and other 
adverse health outcomes (1–5). For example, in the United 
States, HPV types 16 and 18 cause ≈70% of cervical can-
cer, 80% of anal cancer, and 30% of vaginal and vulvar can-
cers (2–5). Furthermore, HPV types 6 and 11 cause >90% 
of cases of anogenital warts (5,6). The economic costs of 
HPV-related genital warts and cervical disease, including 
screening to prevent cervical cancer, are estimated to be at 
least $4 billion annually in the United States (7,8).
In June 2006, the US Food and Drug Administration 
approved a quadrivalent (HPV 6, 11, 16, 18) vaccine (Gar-
dasil, manufactured by Merck & Co., Inc. [Whitehouse 
Station, NJ, USA]) for use in girls and women 9–26 years 
of age (5). The efﬁ  cacy of this vaccine is almost 100% if 
given to young women before sexual exposure (3,5,9). Also 
in June 2006, the US Advisory Committee on Immuniza-
tion Practices recommended routine HPV vaccination for 
girls 11–12 years of age (3). The vaccine series can be initi-
ated in girls as young as 9 years, and catch-up vaccination 
is recommended for girls and young women of ages 13–26 
years who have not received the HPV vaccine previously or 
who have not completed the full vaccine series (3).
In anticipation of the approval of new HPV vaccines, 
several studies have been conducted to estimate the poten-
tial cost-effectiveness of HPV vaccination in the United 
States in terms of the cost per quality-adjusted life year 
(QALY) saved (1,9–13). With 1 exception (1), these stud-
ies applied a Markov model, a decision model, a dynamic 
transmission model, or a combination thereof (see Dasbach 
et al. [14] for a review of HPV models). To complement 
these existing studies, we developed a simpliﬁ  ed model to 
estimate the cost-effectiveness of adding HPV vaccination 
of 12-year-old girls to existing cervical cancer screening 
practices in the United States. Our approach was similar 
to that used by IOM (1) in that we estimated the potential 
beneﬁ  ts of HPV vaccination based on current, age-speciﬁ  c 
incidence rates of HPV-related outcomes. Additionally, 
our analysis extended the IOM approach to reﬂ  ect a more 
current understanding of the vaccine’s characteristics and 
to include the potential beneﬁ  ts of preventing HPV-related 
anal, vaginal, vulvar, and oropharyngeal cancers.
Methods
Similar to the IOM approach, we used spreadsheet 
software to build an incidence-based model of the health 
and economic effects of HPV-related health outcomes in 
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the absence of HPV vaccination. We then examined how 
these effects might change over time because of HPV vac-
cination, based on factors such as the number of 12-year-
old girls vaccinated each year and vaccine efﬁ  cacy. We ad-
opted a societal perspective and included all direct medical 
costs (2005 US$) and beneﬁ  ts regardless of who incurred 
the costs or received the beneﬁ  ts (15,16). The study ques-
tion we addressed was “What is the cost per QALY gained 
by adding vaccination of 12-year-old girls to existing cervi-
cal cancer screening practices in the United States?”
Population Model
A hypothetical population of persons 12–99 years of 
age was created as follows. First, the number of 12-year-old 
girls was based on recent sex-speciﬁ  c population estimates 
(17). The number of 13-year-old girls was calculated as the 
product of the number of 12-year-olds and the probability 
of survival (using recent mortality data) from age 12 years 
to age 13 years. The number of 14-year-old girls and the 
number of persons of all subsequent ages through 99 years 
were calculated in an analogous manner. We assumed that 
the number of 12-year-olds each year was constant over 
time so that the age distribution of the population was con-
stant over time as well.
Vaccine Coverage, Efﬁ  cacy, and Costs
We assumed the HPV vaccine would be adminis-
tered to 12-year-old girls starting in year 1 and continu-
ing through year 100. We assumed that vaccinated girls 
would receive the full vaccine series (3 doses) before age 
13 years. Vaccination coverage (the percentage of 12-year-
old girls vaccinated) was assumed to increase linearly for 
the ﬁ  rst 5 years to 70% and to remain at 70% thereafter 
(9). Vaccination efﬁ  cacy was assumed to be 100%, on the 
basis of trials showing high efﬁ  cacy of prophylactic HPV 
vaccines against persistent infection and vaccine type–spe-
ciﬁ  c cervical intraepithelial neoplasia (CIN) grades 2 and 3 
(3,18–21). The duration of vaccine protection was assumed 
to be lifelong, and the cost of vaccination was set to $360 
per series (9).
Adverse Health Outcomes Averted by Vaccination
We examined the following HPV-related health out-
comes: cervical cancer; CIN grades 1, 2, and 3; genital 
warts; and, in some analyses, anal, vaginal, vulvar, and se-
lected oropharyngeal cancers. The age-speciﬁ  c incidence 
rates of the HPV-related health outcomes were used to es-
timate the potential reduction in these outcomes that could 
be obtained through vaccination.
Age-speciﬁ  c cancer incidence rates were derived from 
2003 population-based cancer registries that participate in 
the Centers for Disease Control and Prevention’s National 
Program of Cancer Registries (NPCR) and the National 
Cancer Institute’s Surveillance, Epidemiology, and End 
Results Program (SEER) (22,23). Together, the 2 cancer 
registries covered ≈96% of the US population in 2003 (22). 
The cancer incidence rates we applied were conservative 
because we included only certain morphology (histology) 
codes, which limited cervical cancers to cervical carcino-
mas (squamous cell, adenocarcinoma, adenosquamous, 
and other carcinoma) and which limited all other noncervi-
cal cancers to squamous cell carcinomas only (24). We did 
not include in situ cancers from the cancer registries. We 
limited oropharyngeal cancers to selected sites most com-
monly associated with HPV (base of tongue, tonsillar, and 
other oropharyngeal sites as described in the online Tech-
nical Appendix, available from www.cdc.gov/EID/con-
tent/14/2/244-Techapp.pdf) (24).
Age-speciﬁ  c incidence rates of CIN grades 1, 2, and 3, 
and prevalence rates of genital warts were based on estimates 
obtained from the literature (25,26). We used prevalence es-
timates for genital warts because age-speciﬁ  c incidence esti-
mates were not available (online Technical Appendix).
Cervical Cancer Screening
The incidence rates of CIN and cervical cancers that 
we applied in our model are those that arise in the context 
of current cervical cancer screening and sexually transmit-
ted disease prevention activities in the United States. Be-
cause these prevention activities are reﬂ  ected in the inci-
dence rates of CIN and cervical cancer that we applied in 
our model, no information about these prevention activities 
(e.g., coverage and frequency of cervical cancer screening) 
was required in our analysis.
Costs Averted and QALYs Saved by Vaccination
The cervical cancer treatment costs averted by vac-
cination were calculated each year by multiplying the 
age-speciﬁ  c number of cervical cancer cases averted by 
the vaccine in that year by the estimated cost per case of 
cervical cancer (online Technical Appendix). The number 
of QALYs saved by preventing cervical cancer was calcu-
lated for each year by multiplying the age-speciﬁ  c number 
of cervical cancer cases averted by the vaccine in that year 
by the estimated age-speciﬁ  c number of QALYs lost per 
case of cervical cancer (online Technical Appendix). For 
other health outcomes (other cancers, CIN 1, CIN 2, CIN 
3, and genital warts), the treatment costs averted and QA-
LYs saved by vaccination were estimated in an analogous 
manner.
Age-speciﬁ  c Estimates of Direct Medical Costs 
and QALYs Lost per Adverse Health Outcome
The estimated direct medical cost per case of cervical 
cancer and other HPV-related health outcomes was based on 
several sources (7,10,12,26–35). The age-speciﬁ  c estimates 
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of the discounted number of QALYs lost per case of an 
HPV-related heath outcome (e.g., cervical cancer) were 
based on published estimates of the quality of life without 
these adverse health outcomes (36) and the estimated re-
duction in quality of life associated with the HPV-related 
health outcome (1,10,12,37) (online Technical Appendix).
Incremental Cost per QALY Gained
Vaccination costs, averted treatment costs, and the 
number of QALYs saved were calculated for each year 
over a 100-year period, discounted to present value by us-
ing an annual discount rate of 3% (9). The incremental cost 
per QALY gained by adding vaccination to existing cervi-
cal cancer screening was calculated as the net cost of vacci-
nation divided by the number of QALYs gained by adding 
vaccination to existing screening, where the net cost of vac-
cination is the cost of vaccination minus the treatment costs 
averted by adding vaccination to existing screening (16).
Herd Immunity Scenario
To examine how the estimated cost-effectiveness of 
vaccination might change if the beneﬁ  ts of herd immuni-
ty were included, we assumed an additional effect of the 
vaccine on nonvaccinated persons, including a reduction 
in genital warts in men. The online Technical Appendix 
provides details of the methods and assumptions used to 
estimate these additional beneﬁ  ts.
Cohort Model
To make our results more comparable to Markov mod-
els of an age cohort, we modiﬁ  ed our population model 
to examine the beneﬁ  ts of vaccination of a single cohort 
of 12-year-old girls over time. Vaccination costs were in-
curred in the ﬁ  rst year only, and the beneﬁ  ts of vaccinat-
ing the 12-year-old cohort were calculated through age 99 
years. Because Markov models of age cohorts typically do 
not include transmission dynamics, we did not consider the 
potential beneﬁ  ts of herd immunity in the cohort model.
Base Case Analyses
Using base-case parameter values (see online Techni-
cal Appendix), we estimated the cost-effectiveness of HPV 
vaccination by using 12 variations of the model. These 12 
variations consisted of 4 permutations (including vs. ex-
cluding the noncervical cancers and including vs. exclud-
ing the beneﬁ  ts of preventing HPV types 6 and 11) of 3 
model versions (population model with and without herd 
immunity, cohort model without herd immunity).
Sensitivity Analyses
We performed sensitivity analyses to examine how 
changes in the base-case parameter values inﬂ  uenced the 
estimated cost-effectiveness of vaccination. We ﬁ  rst exam-
ined how the cost-effectiveness estimates of the population 
model’s herd immunity scenario changed when assump-
tions about the degree of the effect of herd immunity were 
changed. The remainder of the sensitivity analyses focused 
on the population model of the quadrivalent HPV vaccine 
without the adjustment for herd immunity.
We performed 1-way sensitivity analyses in which we 
varied 1 set of parameter values while holding other param-
eters at their base-case values. The parameters we varied 
included the cost of the vaccine series ($300, $490), vac-
cine efﬁ  cacy (95%, 99%), the cost per case of all HPV-re-
lated health outcomes (±25% of their base-case values); the 
discount rate (0%, 5%); the time horizon over which vacci-
nation costs and beneﬁ  ts were assumed to accrue (25 years, 
50 years); the incidence rates of health outcomes (±25% of 
their base-case values for CIN 1, CIN 2, CIN 3, and genital 
warts, and the lower and upper bound ranges of the 95% 
conﬁ  dence interval from the NPCR and SEER data for can-
cers); the percentage of each health outcome attributable 
to HPV vaccine types (±20% of their base-case values); 
and the number of lost QALYs associated with each HPV 
outcome. We manipulated the last number by varying the 
reduction in quality of life (±50% of the base-case values) 
associated with all HPV-related health outcomes and by 
varying the stage-speciﬁ  c survival probabilities for HPV-
related cancers (±2 standard errors). We also performed 
multiway sensitivity analyses by varying >2 sets of these 
parameter values simultaneously.
The parameters that were varied in the sensitivity anal-
yses comprised almost all of the parameters in the model. 
Exceptions included duration of vaccine protection (which 
is difﬁ  cult to modify in our model without sacriﬁ  cing the 
simplicity of our approach), vaccine coverage (which does 
not affect our results except when herd immunity is as-
sumed), and other parameters such as age-speciﬁ  c death 
rates, which are not subject to considerable uncertainty.
Comparison to Previous Cost-Effectiveness Studies
We compared our results with previously published 
estimates of the cost-effectiveness of HPV vaccination. To 
do so, we modiﬁ  ed the parameter inputs to match as closely 
as possible several key attributes of the models applied in 
these previous studies (online Technical Appendix).
Results
Under base-case parameter values, the estimated cost 
per QALY gained by adding vaccination of 12-year-old 
girls to existing cervical cancer screening was $3,906–
$14,723, depending on the type of model applied (cohort 
vs. population), whether herd immunity effects were as-
sumed, the types of HPV targeted by the vaccine (bivalent 
vs. quadrivalent), and whether the beneﬁ  ts of preventing 
other cancers in addition to cervical cancer were included 
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(Table 1). If all other factors were equal, the estimated cost 
per QALY gained by vaccination was lower when herd 
immunity effects were assumed, when protection against 
HPV types 6 and 11 (rather than just HPV types 16 and 18) 
was included, and when the beneﬁ  ts of preventing other 
cancers in addition to cervical cancer were included.
Prevention of HPV-related health outcomes resulted in 
averted treatment costs and QALYs saved. For example, 
in the population model of the quadrivalent vaccine (when 
herd immunity beneﬁ  ts and the beneﬁ  ts of preventing can-
cers other than cervical were excluded), reductions in CIN, 
cervical cancer, and genital warts accounted for ≈70%, 
19%, and 12% of the averted costs, respectively, and ≈33%, 
54%, and 13% of the saved QALYs, respectively.
Sensitivity Analyses
The cost-effectiveness ratios did not change substan-
tially when we modiﬁ  ed the assumptions in the population 
model about the effect of herd immunity. When varying 
the effect of herd immunity, the cost per QALY gained by 
vaccination was $3,423–$7,596 for the quadrivalent vac-
cine and $8,549–$12,354 for the bivalent vaccine, when 
the beneﬁ  ts of preventing cancers other than cervical were 
excluded (results not shown).
In the 1-way sensitivity analyses of the population 
model (excluding assumed herd immunity effects), the 
discount rate and the time horizon had the greatest effect 
on the estimated cost per QALY gained (Table 2). When 
the discount rate was varied from 0% to 5%, the cost per 
QALY gained ranged from $675 to $24,901 (and from <$0 
to $21,966 when other cancers in addition to cervical cancer 
were excluded). When the time horizon was varied from 25 
to 50 years (rather than the base-case value of 100 years), 
the cost per QALY gained ranged from $21,600 to $81,786 
(and from $19,943 to $81,398 when other cancers in addi-
tion to cervical cancer were included). Changes in the other 
sets of parameter values (such as costs and QALYs associ-
ated with HPV-related health outcomes) also affected the 
results, but to a lesser degree than changes in the discount 
rate and time horizon (Table 2). In the multiway sensitivity 
analyses, simultaneously changing 2 sets of parameter val-
ues resulted in estimated costs per QALY gained of <$0 to 
$4,606 when parameter values more favorable to vaccina-
tion were applied and estimated costs per QALY gained of 
$17,825 to $36,503 when parameter values less favorable 
to vaccination were applied (Table 3).
In the best and worst case scenarios (when all 6 se-
lected sets of parameters were set to values more favorable 
and less favorable to vaccination, respectively), the cost per 
QALY gained was <$0 and $122,976, respectively (<$0 
and $115,896 when including other cancers in addition to 
cervical cancer) (Table 3). However, much of the varia-
tion in the best and worst case scenarios was attributable 
to changes in the discount rate and the time horizon. For 
example, when the worst case scenario was modiﬁ  ed to in-
clude a discount rate of 3% (rather than 5%), the estimated 
cost per QALY gained (when the beneﬁ  ts of preventing 
cancers other than cervical were excluded) was ≈$75,000 
when applying a 50-year time horizon and $41,000 when 
applying a 100-year time horizon (results not shown).
Comparison with Previous Cost-Effectiveness Studies
Estimates from the simpliﬁ  ed model were quite consis-
tent with published estimates (Table 4). The absolute differ-
ence between the estimated cost per QALY gained by vacci-
nation as estimated by our simpliﬁ  ed model and as estimated 
by the more complex models did not exceed $4,000.
Discussion
We developed a simple model to estimate the cost-ef-
fectiveness of HPV vaccination in the context of current 
cervical cancer screening in the United States. We found 
that the cost per QALY gained by adding routine vacci-
nation of 12-year-old girls to existing screening practices 
ranged from $3,906 to $14,723 under base-case parameter 
values (depending on the model version we applied) and 
ranged from <$0 (cost-saving) to $122,976 in the sensitiv-
ity analyses when several key parameter values were var-
ied. Our results were consistent with results of published 
studies based on more complex models, particularly when 
key assumptions (e.g., vaccine duration, efﬁ  cacy, and cost) 
were similar.
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Table 1. Estimated cost per QALY gained by adding routine HPV vaccination of 12-y-old girls to existing cervical cancer screening in 
the United States* 
Population model 
Parameter No herd immunity, $US  Herd immunity, $US 
Cohort model; 
no herd immunity, $US 
Excluding anal, vaginal, vulvar, and oropharyngeal cancers 
   Vaccine targets HPV types 6,11,16,18  10,294 5,336 8,593
  Vaccine targets HPV types 16,18  14,723 10,318 12,562
Including anal, vaginal, vulvar, and orophayngeal cancers† 
  Vaccine targets HPV types 6,11,16,18  8,137 3,906 6,430
  Vaccine targets HPV types 16,18  11,602 7,848 9,471
*When applying base-case parameter values to 12 model variations. QALY, quality-adjusted life year; HPV, human papillomavirus. 
†The oropharyngeal cancer sites we included were base of tongue, tonsillar, and other sites as described in the online Technical Appendix (available from 
www.cdc.gov/EID/content/14/2/244-Techapp.pdf). RESEARCH
The simplicity of our approach offers advantages and 
disadvantages. The main advantage is that it requires sub-
stantially fewer assumptions than the more complex Mar-
kov and transmission models. For example, there is no need 
to model the probability of HPV acquisition, the possible 
progression from HPV infection to disease, the mixing of 
sex partners, the probability of HPV transmission, and so 
forth. There also is no need to model cervical cancer screen-
ing and sexually transmitted disease prevention activities 
because these activities are reﬂ  ected in the incidence rates 
of HPV-related health outcomes that we applied.
Because we do not model cervical cancer screening 
directly, however, we are unable to use our model to ex-
amine how changes in cervical cancer–screening strategies 
can affect the cost-effectiveness of HPV vaccination, and 
vice versa. For example, HPV vaccination is expected to 
reduce the positive predictive value of abnormal Papanico-
laou (Pap) test results (38). However, our analysis did not 
include the loss in quality of life attributable to the initial 
distress associated with receiving an abnormal Pap result 
(39), regardless of whether it is a false positive. This omis-
sion of the lost QALYs due to abnormal Pap test results 
underestimates the beneﬁ  ts of HPV vaccination because 
vaccination is expected to offer moderate reductions in the 
number of abnormal Pap results overall (38,40). Future 
changes in screening strategies, such as delayed screening, 
could also possibly improve the cost-effectiveness of HPV 
vaccination (12).
Another disadvantage of our approach is that it offers 
only a rough approximation of the cost-effectiveness of HPV 
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Table 2. One-way sensitivity analyses: estimated cost per QALY gained by adding routine vaccination of 12-y-old girls to existing
cervical cancer screening in the United States* 
Cost/QALY gained 
Parameter or parameter set varied 
Values applied in 
sensitivity analysis 
Excluding anal, vaginal, 
vulvar, oropharyngeal 
cancers, $US 
Including anal, vaginal, 
vulvar, oropharyngeal 
cancers, $US 
None NA 10,294 8,137
Vaccine cost per series (base case = $360)  $300, $490  5,811–20,009  4,237–16,587 
Vaccine efficacy (base case = 100%)  95%, 99%  10,566–11,710  8,374–9,369
Cost of cervical cancer, CIN 1–CIN 3, genital 
warts* 
Base case ±25%  6,142–14,446  4,332–11,953 
Reduction in quality of life due to HPV-related 
health outcomes 
Base case ±50%†  7,720–15,519  6,141–12,135 
Incidence rates of cervical cancer, CIN 1–CIN 3, 
genital warts‡ 
Base case ±25%†  6,999–16,333  5,181–13,379 
% of health outcomes attributable to HPV vaccine 
types 
Base case ±20%  6,014–17,020  4,400–13,987 
Discount rate (base case = 3%)  0%, 5%  675–24,901 <0–21,966
Time horizon (base case = 100 y)  25 y, 50 y  21,600–81,786  19,943–81,398 
*When key parameter values were varied in the population model of quadrivalent HPV vaccine (excluding herd immunity). QALY, quality-adjusted life 
year; HPV, human papillomavirus; NA, not applicable; CIN, cervical intraepithelial neoplasia. 
†See text and online Technical Appendix (available from www.cdc.gov/EID/content/14/2/244-Techapp.pdf) for details. 
‡And, when applicable, anal, vaginal, vulvar, and oropharyngeal cancers. 
Table 3. Multiway sensitivity analyses: estimated cost per QALY gained by adding routine vaccination of 12-y-old girls to existing
cervical cancer screening in the United States*† 
Cost per QALY gained 
Parameter or parameter set varied 
Excluding anal, vaginal, 
vulvar cancers, $US. 
Including anal, vaginal, 
vulvar cancers, $US 
Higher cost per case and larger reduction in quality of life for all HPV-related 
health outcomes 
4,606 3,262
Lower cost per case and smaller reduction in quality of life for all HPV-
related health outcomes 
21,779 17,825
Discount rate = 0%; time horizon = 100 y  675 <0
Discount rate = 5%; time horizon = 50 y  36,503 34,539
Higher percentage of health outcomes attributable to HPV vaccine types; 
higher incidence of HPV-related health outcomes 
3,815 1,882
Lower percentage of health outcomes attributable to HPV vaccine types; 
lower incidence of HPV-related health outcomes 
24,250 20,265
All variables above (best-case scenario)  <0 <0
All variables above (worst-case scenario)  122,976 115,896
*When key parameter values were simultaneously varied in the population model of quadrivalent HPV vaccine (excluding herd immunity). QALY, quality-
adjusted life year; HPV, human papillomavirus; 
†The lower and upper bound ranges were the same as described in the1-way sensitivity analyses, except for the time horizon, which was varied from 50 
y to 100 y. Human Papilllomavirus Vaccination
vaccination and is not suitable for examining strategies such 
as vaccination of boys and men. In addition, although many 
of the parameter values and assumptions in our model can 
be modiﬁ  ed with ease, changing the assumption of lifelong 
duration of protection or examining vaccination at older ages 
would require the incorporation of assumptions about the in-
cidence and natural history of HPV to account for the prob-
ability of acquiring HPV (before vaccination or after vaccine 
immunity wanes) and the subsequent probability of adverse 
HPV-attributable health outcomes. However, we can address 
the issue of waning immunity by assigning a higher cost per 
vaccination series (as in the sensitivity analyses) to reﬂ  ect 
the cost of a booster.
Another limitation of our approach is the uncertainty in 
the key parameter values, such as the cost and loss in qual-
ity of life associated with HPV-related health outcomes, 
the percentage of health outcomes attributable to each type 
of HPV targeted by the vaccine, and the incidence of CIN 
and genital warts. However, our results were fairly robust 
in response to changes in these key parameter values. For 
example, when simultaneously varying the costs of HPV-
related health outcomes and the loss in QALYs associated 
with HPV-related health outcomes, we found that the esti-
mated cost per QALY gained by vaccination ranged from 
$3,262 to $21,779.
Our adjustments for the effect of herd immunity were 
arbitrary; we simply assumed an additional effect of vac-
cination in the nonvaccinated population. However, our re-
sults did not vary substantially (in absolute terms) when the 
assumed effect of herd immunity was varied. For example, 
the estimated cost per QALY gained by quadrivalent vacci-
nation (including herd immunity and excluding the beneﬁ  ts 
of preventing cancers other than cervical) was $5,336 in 
the base case and ranged from $3,423 to $7,596 when the 
adjustments for the effects of herd immunity (including the 
impact on genital warts in males) were varied. We also note 
that the beneﬁ  ts to nonvaccinated persons were assumed 
to occur only in nonvaccinated persons of similar ages to 
those vaccinated. This restriction may have understated the 
potential beneﬁ  ts of herd immunity.
Our analysis did not address all of the potential costs 
and beneﬁ  ts of vaccination. For example, the cost-effec-
tiveness estimates would have been more favorable to vac-
cination if we had included the potential for cross-protec-
tion against high-risk HPV types besides 16 and 18 (21); 
the prevention of anal, vaginal, and vulvar cancer precur-
sor lesions (as demonstrated in the supplemental analysis 
in the online Technical Appendix); the prevention of other 
cancers not included in this analysis (such as anal can-
cer and oropharyngeal cancers in male patients); and the 
prevention of other HPV-related health outcomes such as 
recurrent respiratory papillomatosis. Conversely, the cost-
effectiveness estimates would have been less favorable to 
vaccination if we had included the potential for HPV type 
replacement (i.e., an increase in HPV types not protected 
against by vaccination), waning immunity, and the possible 
costs and loss in quality of life associated with adverse side 
effects of vaccination.
A key ﬁ  nding from this analysis was that the choice of 
discount rate and time horizon has a substantial inﬂ  uence 
on the estimated cost-effectiveness of vaccination. Because 
the costs of HPV vaccination begin to accrue immediately 
but the full beneﬁ  ts of vaccination are not realized for many 
years, the cost-effectiveness of vaccination becomes less 
favorable when higher discount rates are applied or when 
shorter time horizons are examined.
Another key ﬁ  nding was that the potential beneﬁ  ts of 
preventing anal, vaginal, vulvar, and oropharyngeal can-
cers offer nontrivial improvements in the estimated cost-
effectiveness of HPV vaccination. The inclusion of these 
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Table 4. Summary of previously published models and estimates of the cost per QALY gained by adding routine HPV vaccination of 
12-y-old girls to existing cervical cancer screening in the United States*† 
Variable Goldie et al. 2004 (10)
Sanders and Taira 
2003 (11) Taira et al. 2004 (13) Elbasha et al. 2007 (9)
Key assumptions in published models 
  Target of HPV vaccine HPV 16,18 High-risk HPV types HPV 16,18 HPV 6,11,16,18
  Efficacy of vaccine 90% 75% 90% 100%‡
  Vaccine cost per series $393 $300 $300 + $100 booster $360
   Base year of $US 2002 2001 2001 2005
Estimated cost per QALY of vaccination 
  Published model estimate $24,300 $12,700§ $14,600 $3,000
 Simplified  model  estimate $20,600 $8,700 $17,100 $5,300
*QALY, quality-adjusted life year; HPV, human papillomavirus. 
†In all comparisons, the simplified model was modified (as necessary) so that the assumptions regarding the target of the HPV vaccine, vaccine efficacy 
and cost, vaccine duration of protection (except in the comparison to Taira and colleagues [13], as noted in the online Technical Appendix, available from 
www.cdc.gov/EID/content/14/2/244-Techapp.pdf), and the base year of US$ were consistent with the published models (online Technical Appendix). The 
simplified model estimate was based on the cohort model in the comparisons with the findings of Goldie et al. (10) and Sanders and Taira (11) and was 
based on the population model (assuming transmission effects) in the comparison with the estimates of Taira and colleagues (13) and Elbasha and 
colleagues (9). 
‡Elbasha and colleagues (9) assumed 90% protection against infection with HPV and 100% protection against HPV-related disease. 
§To enhance comparability, the published estimate from Sanders and Taira (11) was based on their sensitivity analyses when assuming lifetime duration 
of vaccination, not their base-case estimate of $22,800 when 10-y vaccine duration of protection was assumed. RESEARCH
additional beneﬁ  ts decreased the cost per QALY gained by 
vaccination by ≈$2,200 (or 21%) in the population mod-
el (without herd immunity), by ≈$1,400 (or 27%) in the 
population model (with herd immunity), and by ≈$2,200 
(or 25%) in the cohort model. Future studies that develop 
better estimates of the cost and loss in quality of life as-
sociated with these cancers could more accurately estimate 
the effects of these additional beneﬁ  ts on the cost-effective-
ness of HPV vaccination. Despite the limitations discussed 
above, our simpliﬁ  ed model provides useful estimates of 
cost-effectiveness of HPV vaccination in the United States. 
Our results were consistent with previous studies based 
on more complex models. This consistency is reassuring 
because models of various degrees of complexity will be 
essential tools for policy makers in the development of op-
timal HPV vaccination strategies.
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